Document Detail


Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]).
MedLine Citation:
PMID:  20691307     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The optimal blood pressure (BP) to prevent major adverse outcomes (death, myocardial infarction, and stroke) for patients with hypertension and coronary artery disease who have undergone previous revascularization is unknown but might be influenced by the type of revascularization procedure. We analyzed data from the INternational VErapamil SR-Trandolapril STudy, focusing on the relation between BP and the outcomes of 6,166 previously revascularized patients, using the 16,410 nonrevascularized patients as a reference group. The previous revascularization strategy consisted of coronary artery bypass grafting (CABG, 45.2%), percutaneous coronary intervention (PCI, 42.1%), or both (CABG+PCI, 12.8%). Patients who had undergone both CABG+PCI and CABG-only had a greater adverse outcome risk (adjusted hazard ratio 1.27% and 1.20%, 95% confidence interval 1.06 to 1.53 and 1.07 to 1.35, respectively). The risk was similar for PCI-only patients (adjusted hazard ratio 1.04, 95% confidence interval 0.92 to 1.19). The relations between the adjusted hazard ratio and on-treatment BP appeared J-shaped for each revascularization strategy, accentuated for PCI and diastolic BP (DBP), but excepting CABG only and DBP for which the relation was linear and positive. In conclusion, major adverse outcomes were more frequent in patients with coronary artery disease who had undergone previous CABG, with or without PCI, compared to those with previous PCI only. This likely reflected more severe vascular disease. The relation to systolic BP was J-shaped for each strategy. Among those patients with previous CABG only, the linear relation with DBP suggested that more complete revascularization might attenuate hypoperfusion at a low DBP. The management of BP might, therefore, require modification of targets according to the revascularization strategy to improve outcomes.
Authors:
Scott J Denardo; Franz H Messerli; Efrain Gaxiola; Juan M Aranda; Rhonda M Cooper-Dehoff; Eileen M Handberg; Yan Gong; Annette Champion; Qian Zhou; Carl J Pepine
Related Documents :
10372167 - Stroke volume variability--cardiovascular response to orthostatic maneuver in patients ...
11432307 - Risk factors for mortality in primary isolated coronary artery bypass grafting surgery.
23305297 - A clinical phenotype of adverse response to biventricular pacing: a case series.
12667127 - Application of off-pump coronary artery bypass grafting for patients with acute coronar...
17250647 - Acute coronary ligation in the dog induces time-dependent transitional changes in mitoc...
16003697 - Consideration of the total st-segment deviation on the initial electrocardiogram for pr...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  106     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-09     Completed Date:  2010-09-21     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  498-503     Citation Subset:  AIM; IM    
Affiliation:
University of Florida College of Medicine, Gainesville, FL, USA. scott.denardo@medicine.ufl.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angioplasty, Balloon, Coronary*
Antihypertensive Agents / therapeutic use
Blood Pressure
Coronary Artery Bypass*
Coronary Artery Disease / complications,  therapy*
Female
Humans
Hypertension / complications,  drug therapy*
Male
Middle Aged
Myocardial Revascularization
Treatment Outcome
Grant Support
ID/Acronym/Agency:
K23 HL086558-04/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antihypertensive Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of Everolimus- Versus Paclitaxel-Eluting Stents Implanted in Patients With Diabetes Melli...
Next Document:  Three-Year Outcomes Following Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in an Unselect...